During the past decade, VIN-Julie Schwartzbard conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 2 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "VIN-Julie Schwartzbard" are "Alzheimer Disease" (3 trials), "Chronic Low-back Pain" (3 trials), "Diabetic Peripheral Neuropathic Pain" (3 trials), "Osteoarthritis" (2 trials) and "Alzheimer's Disease" (1 trials). Many other conditions were trialed in "VIN-Julie Schwartzbard" in a lesser frequency.

Most popular intervention types in "VIN-Julie Schwartzbard" are "Drug" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "LY3556050" (3 trials), "Donanemab" (2 trials), "LY3016859" (2 trials) and "LY3526318" (2 trials). Other intervention names were less common.

The vast majority of trials in "VIN-Julie Schwartzbard" are 12 trials for "All" genders.

Currently, there are NaN active trials in "VIN-Julie Schwartzbard". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in VIN-Julie Schwartzbard, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in VIN-Julie Schwartzbard, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".